| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Tricaprin is a triglyceride that, after oral administration, is hydrolyzed to decanoic acid (DA). Decanoic acid binds to and partially activates peroxisome proliferator-activated receptors (PPARs), including PPAR-γ, PPAR-α, and PPAR-β/δ, without inducing adipogenesis. By activating PPARs, it may improve insulin sensitivity and reduce androgen production. It also exhibits anti-androgenic and anti-hyperglycemic properties.
|
|---|---|
| ln Vitro |
Tricaprin exhibits anti-androgenic and anti-hyperglycemic properties. As a prodrug of decanoic acid, its biological activity is mediated by the released fatty acid. Decanoic acid partially activates PPAR-γ, PPAR-α, and PPAR-β/δ without inducing adipogenesis. It may improve insulin sensitivity and reduce androgen production.
|
| ln Vivo |
In vivo, Tricaprin is hydrolyzed to decanoic acid after oral administration. Decanoic acid then binds to and partially activates PPARs. This leads to potential anti-androgenic and anti-hyperglycemic effects. Tricaprin may improve insulin sensitivity and reduce androgen production in preclinical models.
|
| Enzyme Assay |
In vitro assays for Tricaprin typically measure its hydrolysis to decanoic acid by esterases or lipases. The release of decanoic acid can be quantified by chromatographic methods. PPAR activation can be assessed using cell-based reporter assays, where cells expressing PPARs and a luciferase reporter are treated with decanoic acid, and luciferase activity is measured.
|
| Cell Assay |
In vitro cellular assays for Tricaprin involve treating cells with the compound or its metabolite, decanoic acid, to assess effects on adipogenesis, insulin sensitivity, and androgen production. PPAR activation can be measured using reporter gene assays. Adipogenesis can be assessed by Oil Red O staining in adipocyte differentiation models.
|
| Animal Protocol |
In vivo animal models for Tricaprin are used to study its metabolic effects. Rodent models of diabetes or obesity are treated with the compound, and parameters such as blood glucose, insulin sensitivity, and lipid profiles are measured. Its anti-androgenic effects can be studied in models of androgen excess, such as polycystic ovary syndrome.
|
| ADME/Pharmacokinetics |
After oral administration, Tricaprin is hydrolyzed to decanoic acid. Decanoic acid is a medium-chain fatty acid that is rapidly absorbed and metabolized. It is transported to the liver where it undergoes beta-oxidation to produce energy. Its pharmacokinetics are characterized by rapid absorption and metabolism, typical of medium-chain triglycerides.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Tricaprin is characteristic of medium-chain triglycerides, which are generally recognized as safe (GRAS) for use in food. It is well-tolerated at typical doses. High doses may cause gastrointestinal discomfort, including diarrhea and nausea. Its use as a food additive and in pharmaceuticals is well-established.
|
| References | |
| Additional Infomation |
Tricapinin is a triglyceride derived from the acylation of the three hydroxyl groups of glycerol by decanoic acid (decanoic acid). It is both a triglyceride and a decanoic acid ester. Tricapinin has been reported to be present in the California umbellularia (Umbellularia californica), and relevant data are available. Tricapinin is an orally effective prodrug of decanoic acid (DA), a 10-carbon fatty acid and a major component of medium-chain triglyceride oils, possessing potential anti-androgenic and hypoglycemic effects. After oral administration, tricapinin is hydrolyzed to decanoic acid, which can bind to and partially activate peroxisome proliferator-activated receptor (PPAR)-γ, as well as PPAR-α and PPAR-β/δ, without inducing lipogenesis. Furthermore, tricapinin may improve insulin sensitivity and reduce androgen production.
Tricaprin is a medium-chain triglyceride and the major component of MCT oils. It is an orally bioavailable prodrug of decanoic acid. Decanoic acid activates PPARs, improving insulin sensitivity and reducing androgen production. It has anti-androgenic and anti-hyperglycemic properties and is used in food, pharmaceuticals, and cosmetics. |
| Molecular Formula |
C33H62O6
|
|---|---|
| Molecular Weight |
554.85
|
| Exact Mass |
554.454
|
| CAS # |
621-71-6
|
| PubChem CID |
69310
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
578.6±17.0 °C at 760 mmHg
|
| Melting Point |
31-32 °C
|
| Flash Point |
233.3±21.0 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.461
|
| LogP |
12.52
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
39
|
| Complexity |
543
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LADGBHLMCUINGV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H62O6/c1-4-7-10-13-16-19-22-25-31(34)37-28-30(39-33(36)27-24-21-18-15-12-9-6-3)29-38-32(35)26-23-20-17-14-11-8-5-2/h30H,4-29H2,1-3H3
|
| Chemical Name |
2,3-di(decanoyloxy)propyl decanoate
|
| Synonyms |
Capric acid triglyceride; Caprin; Tricaprin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~180.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8023 mL | 9.0114 mL | 18.0229 mL | |
| 5 mM | 0.3605 mL | 1.8023 mL | 3.6046 mL | |
| 10 mM | 0.1802 mL | 0.9011 mL | 1.8023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
